Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Net Margin (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Net Margin for 11 consecutive years, with 5335.93% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 213738.0% to 5335.93% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 199048.08% through Dec 2025, up 19915716.0% year-over-year, with the annual reading at 32575.5% for FY2025, 3237650.0% down from the prior year.
  • Net Margin for Q4 2025 was 5335.93% at Cartesian Therapeutics, up from 4448.99% in the prior quarter.
  • The five-year high for Net Margin was 5335.93% in Q4 2025, with the low at 2379.12% in Q4 2023.
  • Average Net Margin over 5 years is 439.93%, with a median of 19.68% recorded in 2022.
  • The sharpest move saw Net Margin crashed -241421bps in 2023, then skyrocketed 557767bps in 2024.
  • Over 5 years, Net Margin stood at 40.88% in 2021, then decreased by -14bps to 35.09% in 2022, then plummeted by -6880bps to 2379.12% in 2023, then skyrocketed by 234bps to 3198.55% in 2024, then skyrocketed by 67bps to 5335.93% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 5335.93%, 4448.99%, and 1806.73% for Q4 2025, Q2 2025, and Q1 2025 respectively.